Thema: KR7207940008
Samsung Biologics, KR7207940008
covid-19-4987726_1280.jpg - Foto: THN
Samsung Biologics stock: 20% sales growth target after Q3 beat
Samsung Biologics stock enters the final quarter after stronger-than-expected operating results. Labor talks and expansion spending remain key investor issues.
ad-hoc-news.de, heute 01:42 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics clears 87.88% tender hurdle: what it means ...
Final results on October 16 showed 87.88 percent tendered. For Samsung Biologics stock, the deal means a 26 October vote and a 2026 completion target.
ad-hoc-news.de, 19.10.26 02:40 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics stock gets a new contract through 2031 ...
Samsung Biologics stock closed at KRW 1,354,000 on October 2 2026 after a KRW 93,478,620,000 contract. Second-quarter revenue rose 30 percent and operating profit 23 percent ...
ad-hoc-news.de, 05.10.26 20:42 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics signs KRW 93.50 billion deal. 25 analysts ...
Second-quarter revenue hit KRW 1,320.90 billion, up 30.14 percent year over year. Samsung Biologics stock has a KRW 1.97 million target from 26 analysts.
ad-hoc-news.de, 05.10.26 15:03 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics stock edges higher as tender offer and ...
Samsung Biologics stock is moving in a tight range as investors weigh a 3 trillion won capital increase a planned 1.46 billion Swiss franc tender offer for PolyPeptide Group ...
ad-hoc-news.de, 01.09.26 21:04 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics Stock - Sunday background on capacity ...
Samsung Biologics is one of the largest pure-play biologics contract manufacturers worldwide. With no fresh market-moving headlines today the focus is on a Sunday background ...
ad-hoc-news.de, 21.06.26 20:59 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics Co Ltd stock (KR7207940008): contract ...
Samsung Biologics has secured a follow-on order highlighted in Rapid Micro Biosystems’ latest update underscoring the Korean CDMO’s role in global biologics manufacturing ...
ad-hoc-news.de, 19.05.26 23:15 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics Co Ltd stock (KR7207940008): earnings ...
Samsung Biologics Co Ltd has expanded capacity and reported solid 2024 results underscoring its role as a major global contract manufacturer for biopharmaceuticals with relevance ...
ad-hoc-news.de, 16.05.26 08:58 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics stock (KR7207940008): CDMO leader navigates ...
Samsung Biologics South Korea's largest contract manufacturing organization combines rapid revenue growth with strong profitability. The biopharmaceutical company serves global ...
ad-hoc-news.de, 12.05.26 16:54 Uhr
Samsung Biologics, KR7207940008
Samsung Biologics Co Ltd stock (KR7207940008): Is its CDMO ...
